The Aiforia Clinical Suites

AI assisted diagnostics for the clinical pathology workflow.

Aiforia Clinical AI Model for Breast Cancer; Ki67 and Aiforia®️ Clinical AI Model for Lung Cancer; PD-L1 are CE-IVD marked for diagnostic use in EU and EEA countries.
Aiforia’s other AI Models, Aiforia Clinical Suites and the Aiforia Create software are currently sold for research use only.
Scroll down to read more

The Aiforia Clinical Suites

We are currently developing different Clinical Suites for...

  • The most prevalent cancers in the world: prostate, breast, lung, and more...that is not all!
  • The Aiforia Clinical Suites can cater to any disease thanks our versatile technology.
  • Each Suite is seamlessly integrated into any existing lab setup: PACS, LIS, scanning, staining, scoring definitions, and more! You don’t need to adapt to start using Aiforia’s solutions, we adapt to meet your needs.
Ki67 hotspot 1 clinical

Breast Cancer: Ki67

CE-IVD marked Aiforia® Clinical AI Model for Breast Cancer; Ki67
  • Creates a heatmap assisting the pathologist in automatically finding the critical areas of the sample.

  • Rapidly distinguishes between normal and cancerous tissue supporting the pathologist in the quick detection of tumor epithelium.

  • Automatically scores the Ki67 positive and negative cells of epithelial origin from either WSI or selected image areas, saving the pathologist time.

  • Provides intelligent viewing as the Ki67 AI Model enables viewing and selection of areas with high density of Ki67-positive cells, or hotspots, displaying the results of image analysis.

Read more
laptop

Lung Cancer: PD-L1

CE-IVD marked Aiforia® Clinical AI Model for Lung Cancer; PD-L1
  • Creates a heatmap assisting the pathologist in automatically finding the critical areas of the sample.

  • Rapidly distinguishes between normal and cancerous tissue supporting the pathologist in the quick detection of tumor epithelium.

  • Automatically scores the PD-L1 positive and negative cells of epithelial origin from whole slide images (WSI) saving the pathologist time when evaluating patient samples.

  • Provides intelligent viewing and selection of areas with high density of PD-L1 positive cells displaying the results of image analysis in different magnifications and enables the user to move in different x-y-z-locations, as well as to mark and measure features in the images.

Read more

Are you ready to experience the power of AI?

We are looking for pathology labs to join us in becoming the frontrunners of AI-powered diagnostics.
Infinite clinical possibilities in a single, unified platform.

Each Aiforia Clinical Suite offers the tools you need to transform your clinical workflow:

Aiforia Clinical AI model for diagnostic support

Aiforia Clinical Suite viewer

  • Customized to the specific disease type (i.e. for Breast Cancer, Prostate Cancer, etc.)
  • Case-centric design with focus on slide specific results
  • Enables fast and easy review with context
  • Automatically generates numerical results to a report
  • Displays AI results as masks with high precision on whole slide images 
  • Fast and easy organization of AI findings in the slide by severity

Aiforia Platform for QC and adaptation

  • An intuitive user interface in which you can easily adapt your AI model to accommodate changes if they are needed
  • Easy management and monitoring for QC and auditing purposes
  • Compliant with the FDA’s Good Machine Learning Practices (GMLP), a framework outlining best practices in software engineering and quality management of AI systems

You can also use the Aiforia Clinical AI model for:

PRE-ANALYSIS SCREENING

  • Automatically prioritize cases to focus on the most severe ones first
  • Speed up time to diagnosis and detect more cases 
  • Improve lab and workflow efficiency

POST-ANALYSIS SCREENING

  • To act as a safety net by confirming the decisions of the pathologist and alerting them to potentially suspicious findings 
  • Enabling the detection of more cases and reduce error rates to improve patient safety and outcomes while reducing healthcare costs

Benefits

Work more efficiently

Diagnose more patients in less time and speed up case review

ic_slideincrease_white

Improve accuracy

Improve diagnostic accuracy and be confident in your decision making

ic_define_white

Reduce bias

and standardize sample review therefore democratizing care

ic_reducebias_white

Harness your full potential

Unbind yourself from time-consuming, manual and frustrating tools and processes

Free your time

Allow yourself more time to focus on rare and complex cases

ic_save time_white

Increase output

Detect more cases in less time, take on more patients

ic_output_white-1

Improve patient outcomes

Precise diagnosis permits efficient and personalized therapies to be administered

ic_patientoutcome_white

Enhance service quality

Shorten time to diagnosis and reduce missed diagnoses and misdiagnoses

ic_decisions with confidence_white

Save on cost and time

Significant time savings, 90% less hands-on time for pathologists and reduce misdiagnosis and error while improving treatment accuracy

ic_reduce costs_white

Enhance staff satisfaction

Better workload distribution can be achieved as pathologists spend less time on manual, repetitive tasks

ic_smile_white

Less time waiting

Get your diagnosis and results faster

ic_save time_white

Effective treatment

With a precise diagnosis clinicians are able to treat more effectively

ic_personalcare_white

Democratized care

Samples are reviewed consistently and efficiently ensuring everyone is treated the same

ic_collaborate remotly_white

Reduction in unnecessary interventions

Reducing missed and misdiagnosis means a reduction in the likelihood of unnecessary surgeries or procedures

ic_regression_white
Clinical_Sami (1)

Aiforia Clinical Suite for Prostate Cancer

Demonstration and overview

Watch this presentation with Aiforia’s Director of Application Development, Dr. Sami Blom, to see and hear more about the Aiforia Clinical Suite, with prostate cancer as a case example of what we are currently developing. 

Watch now